RECURSION PHARMACEUTICALS, INC. (RXRX)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch RXRX
See up to 3 months of RXRX. The 7-day demo opens the 1M and 3M ranges and puts RXRX on your watchlist.
Start 7-day demoLatest RXRX insider trades
- Blake Borgeson - DirectorOpen-market sale$242K
Robert Hershberg - DirectorOpen-market sale$125K
About RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. files with the SEC under CIK 0001601830 and is classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
RXRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 157,408 | $644K |
| Grant or award | 2 | 7,985 | |
| Option exercise | 2 | 50,000 | |
RXRX insider transactions (Form 4)
3797 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Blake Borgeson - Director | Open-market sale | Class A Common Stock | 50,000 | $4.84 footnote F2 | $242K | |
| ||||||
| Robert Hershberg - Director | Option exercise | Class A Common Stock | 25,000 | $2.22 | $56K | |
| Robert Hershberg - Director | Open-market sale | Class A Common Stock | 25,000 | $5.00 | $125K | |
| Robert Hershberg - Director | Option exercise | Stock Option (Right to Buy) | 25,000 | $2.22 | $56K | |
 Zavain Dar - Director | Grant or award | Class A Common Stock | 4,607 | $0.00 | - | |
| Dean Y. Li - Director | Grant or award | Class A Common Stock | 3,378 | $0.00 | - | |
| Ben R. Taylor - Officer | Tax withholding / forfeiture | Class A Common Stock | 5,396 | $3.41 | $18K | |
| Najat Khan - Officer | Open-market sale | Class A Common Stock | 22,408 | $3.52 footnote F2 | $79K | |
| ||||||
| Blake Borgeson - Director | Open-market sale | Class A Common Stock | 30,000 | $3.34 | $100K | |
| Najat Khan - Officer | Tax withholding / forfeiture | Class A Common Stock | 80,498 | $3.16 | $254K | |
| David Hallett - Officer | Tax withholding / forfeiture | Class A Common Stock | 26,657 | $3.16 | $84K | |
| Ben R. Taylor - Officer | Tax withholding / forfeiture | Class A Common Stock | 25,018 | $3.16 | $79K | |
| Blake Borgeson - Director | Open-market sale | Class A Common Stock | 30,000 | $3.25 | $98K | |
| Blake Borgeson - Director | Open-market sale | Class A Common Stock | 40,000 | $3.96 footnote F2 | $159K | |
| ||||||
| Zavain Dar - Director | Grant or award | Class A Common Stock | 5,109 | $0.00 | - | |
| Dean Y. Li - Director | Grant or award | Class A Common Stock | 3,747 | $0.00 | - | |
| Blake Borgeson - Director | Grant or award | Class A Common Stock | 88,424 | $0.00 | - | |
| Robert Hershberg - Director | Grant or award | Class A Common Stock | 88,424 | $0.00 | - | |
| Franziska Michor - Director | Grant or award | Class A Common Stock | 88,424 | $0.00 | - | |
| Elaine D. Sun - Director | Grant or award | Class A Common Stock | 88,424 | $0.00 | - | |
| Zavain Dar - Director | Grant or award | Class A Common Stock | 88,424 | $0.00 | - | |
| Dean Y. Li - Director | Grant or award | Class A Common Stock | 88,424 | $0.00 | - | |
| Namandje Bumpus - Director | Grant or award | Class A Common Stock | 88,424 | $0.00 | - | |
| Namandje Bumpus - Director | Open-market sale | Class A Common Stock | 3,963 | $3.18 | $13K | |
| Ben R. Taylor - Officer | Tax withholding / forfeiture | Class A Common Stock | 5,396 | $3.15 | $17K | |
| Christopher Gibson - Director | Other | Class A Common Stock | 40,000 | $0.00 | - | |
| Christopher Gibson - Director | Open-market sale | Class A Common Stock | 40,000 | $3.62 | $145K | |
| Christopher Gibson - Director | Other | Class B Common Stock | 40,000 | $0.00 | - | |
| Najat Khan - Officer | Open-market sale | Class A Common Stock | 23,588 | $3.58 footnote F2 | $84K | |
| ||||||
| Namandje Bumpus - Director | Open-market sale | Class A Common Stock | 4,386 | $3.54 | $16K | |
| Blake Borgeson - Director | Open-market sale | Class A Common Stock | 30,000 | $3.68 | $110K | |
| Christopher Gibson - Director | Other | Class A Common Stock | 40,000 | $0.00 | - | |
| Christopher Gibson - Director | Open-market sale | Class A Common Stock | 40,000 | $3.08 | $123K | |
| Christopher Gibson - Director | Other | Class B Common Stock | 40,000 | $0.00 | - | |
| David Hallett - Officer | Tax withholding / forfeiture | Class A Common Stock | 26,657 | $3.04 | $81K | |
| Najat Khan - Officer | Tax withholding / forfeiture | Class A Common Stock | 62,701 | $3.04 | $191K | |
| Ben R. Taylor - Officer | Tax withholding / forfeiture | Class A Common Stock | 25,018 | $3.04 | $76K | |
Item 1.01
Item 2.02, 7.01, 9.01
Item 5.07
Item 2.02, 7.01, 9.01
Recent RXRX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Borgeson Blake | Director | 50,000 | $242K | View on EDGAR | |
| HERSHBERG ROBERT | Director | 25,000 |
RXRX insider trading FAQ
What is the latest insider trade for RXRX?
RECURSION PHARMACEUTICALS, INC. (RXRX) had 11 insider filings in the last 90 days, with the most recent on 2026-10-07. The full record for RXRX runs to 97 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying RXRX stock?
No insider purchases of RXRX were filed in the last 90 days.
How many insiders are selling RXRX stock?
5 insider sales of RXRX were filed in the last 90 days, totaling $644K.
Where can I see RXRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects RXRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Blake Borgeson view on EDGAR
- - Robert Hershberg view on EDGAR
- - Zavain Dar view on EDGAR
- - Dean Y. Li view on EDGAR
- - Ben R. Taylor view on EDGAR
- - Najat Khan view on EDGAR
- - Blake Borgeson view on EDGAR
- - Najat Khan view on EDGAR
- - David Hallett view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where RXRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow RXRX with a 7-day demo
- RXRX on your watchlist
- Every RXRX Form 4 filing on record
- Up to 3 months of RXRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
